|
|
|
Scientific Literature, cholesterol
-
Abad-Lacruz A, Fernandez-Banares F, Cabre E, Gil A, Esteve M, Gonzalez-Huix F, Xiol X, Gassull MA 1988 The effect of total enteral tube feeding on the vitamin status of malnourished patients with inflammatory bowel disease.
Int. J. Vitam. Nutr. Res. 58: 428-435.
-
Aberle J, Fedderwitz I, Klages N, George E, Beil FU 2007 Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet.
Horm. Metab. Res. 39: 395-397.
-
Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, De Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M 2006 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux.
J. Biol. Chem. 281: 12799-12808.
*
-
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H 2007 Chronic inflammatory autoimmune disorders and atherosclerosis.
Ann. N. Y. Acad. Sci. 1107: 56-67.
*
-
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK 2003 Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis.
Am. J. Surg. Pathol. 27: 441-451.
-
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK 2003 Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy.
Am. J. Surg. Pathol. 27: 1313-1320.
-
Abrahamsson A, Gafvels M, Reihner E, Bjorkhem I, Einarsson C, Eggertsen G 2005 Polymorphism in the coding part of the sterol 12alpha-hydroxylase gene does not explain the marked differences in the ratio of cholic acid and chenodeoxycholic acid in human bile.
Scand. J. Clin. Lab. Invest. 65: 595-600.
*
-
Abrahamsson A, Krapivner S, Gustafsson U, Muhrbeck O, Eggertsen G, Johansson I, Persson I, Angelin B, Ingelman-Sundberg M, Bjorkhem I, Einarsson C, Hooft FM 2005 Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration.
Atherosclerosis 182: 37-45.
-
Acosta-Perez G, Maximina Bertha Moreno-Altamirano M, Rodriguez-Luna G, Javier Sanchez-Garcia F 2008 Differential dependence of the ingestion of necrotic cells and TNF-alpha/IL-1beta production by murine macrophages on lipid rafts.
Scand. J. Immunol. 68: 423-429.
*
-
Adibhatla RM, Hatcher JF 2008 Altered lipid metabolism in brain injury and disorders.
Subcell. Biochem. 49: 241-268.
-
Adibhatla RM, Hatcher JF 2008 Altered lipid metabolism in brain injury and disorders.
Subcell. Biochem. 48: nihpa41041.
*
-
Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-De Vrieze F 2006 Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease.
Neurobiol. Aging 27: 1431-1434.
-
Agte VV, Tarwadi KV 2008 Combination of diabetes and cataract worsens the oxidative stress and micronutrient status in Indians.
Nutrition 24: 617-624.
-
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN 2007 Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005).
J. Am. Vet. Med. Assoc. 231: 79-88.
-
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ 2007 Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Am. J. Ther. 14: 49-62.
-
Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB 2008 Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
Int. J. Cancer 123: 1733-1740.
*
-
Ahuja HS, Szanto A, Nagy L, Davies PJ 2003 The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death.
J. Biol. Regul. Homeost. Agents 17: 29-45.
-
Akaogi J, Barker T, Kuroda Y, Nacionales DC, Yamasaki Y, Stevens BR, Reeves WH, Satoh M 2006 Role of non-protein amino acid L-canavanine in autoimmunity.
Autoimmun. Rev. 5: 429-435.
-
Akhyani M, Ehsani AH, Robati RM, Robati AM 2007 The lipid profile in psoriasis: a controlled study.
J. Eur. Acad. Dermatol. Venereol. 21: 1330-1332.
*
-
Akimoto T, Kobayashi S, Tamura N, Ohsawa T, Kawano T, Tanaka M, Hashimoto H 2005 Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus.
Angiology 56: 601-609.
-
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ 2002 Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.
Mol. Cell. Biol. 22: 2607-2619.
*
-
Akoume MY, Perwaiz S, Yousef IM, Plaa GL 2003 Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Toxicol. Sci. 73: 378-385.
*
-
Akoume MY, Tuchweber B, Plaa GL, Yousef IM 2004 The role of mdr2 in manganese-bilirubin induced cholestasis in mice.
Toxicol. Lett. 148: 41-51.
*
-
Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U 2008 Coagulation status and biochemical and inflammatory markers in multiple sclerosis.
J. Clin. Neurosci. 15: 393-397.
-
Alazmi WM, Fogel EL, Watkins JL, McHenry L, Sherman S, Lehman GA 2007 The effect of biliary sphincterotomy on serum cholesterol level in postcholecystectomy patients: a pilot study.
Can. J. Gastroenterol. 21: 81-84.
-
Albahrani AI, Usher J, Marks E, Ranganath L, Shenkin A 2007 Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report.
J. Med. Case Reports 1: 51.
*
-
Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP 2005 Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis.
Gut 54: 987-993.
*
-
Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, Deuschle U, Koegl M 2006 A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors.
J. Biol. Chem. 281: 4920-4930.
*
-
Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA 2001 Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice.
J. Clin. Invest. 107: 565-573.
*
-
Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T 2008 Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
Acta Radiol. 49: 855-862.
-
Albrecht C, Elliott JI, Sardini A, Litman T, Stieger B, Meier PJ, Higgins CF 2002 Functional analysis of candidate ABC transporter proteins for sitosterol transport.
Biochim. Biophys. Acta 1567: 133-142.
*
-
Aldamiz-Echevarria L, Sanjurjo P, Elorz J, Prieto JA, Perez C, Andrade F, Rodriguez-Soriano J 2006 Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia.
J. Inherit. Metab. Dis. 29: 58-63.
*
-
Alfter K, von Kugelgen I, Haenisch B, Frieling T, Hulsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ 2008 New aspects of liver abnormalities as part of the systemic mast cell activation syndrome.
Liver Int. Jul 23 [Epub ahead of print].
*
-
Alkofer BJ, Chiche L, Khayat A, Deshayes JP, Lepage A, Saloux E, Reznik Y 2005 Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: report of the first case and review of the literature.
Transplant. Proc. 37: 2250-2252.
*
-
Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM 2008 Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.
Dig. Dis. Sci. 53: 1088-1092.
*
-
Allocca M, Crosignani A, Battezzati PM, Gritti A, Podda M 2004 Hypercholesterolaemia is not associated with increased carotid-artery intima and media thickness in primary biliary cirrhosis.
J. Hepatol. 40 Suppl. 1: 159.
-
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM 2006 Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.
Gut 55: 1795-1800.
*
-
Alnounou M, Munoz SJ 2006 Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf]
Practical Gastroenterology April 2006: 92-100. *
-
Alonso L AG 2006 Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy.
Ann. Hepatol. 5: 184-186.
*
-
Alpy F, Tomasetto C 2005 Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.
J. Cell. Sci. 118: 2791-2801.
*
-
Alrefai WA, Gill RK 2007 Bile acid transporters: structure, function, regulation and pathophysiological implications.
Pharm. Res. 24: 1803-1823.
*
-
Alrefai WA, Sarwar Z, Tyagi S, Saksena S, Dudeja PK, Gill RK 2005 Cholesterol modulates human intestinal sodium-dependent bile acid transporter.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G978-G985.
*
-
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D 2008 Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants.
J. Clin. Periodontol. 35: 51-57.
-
Altman RS, Altman LJ, Altman JS 2002 A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris.
Dermatology 204: 232-235.
-
Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP 2004 Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.
Science 303: 1201-1204.
*
-
Aly A, Carlson K, Johansson C, Kirstein P, Rossner S, Wallentin L 1984 Lipoprotein abnormalities in patients with early primary biliary cirrhosis.
Eur. J. Clin. Invest. 14: 155-162.
-
Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S 2006 Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.
Ann. Hepatol. 5: 30-33.
*
-
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG 1985 The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis.
J. Clin. Apheresis 2: 219-223.
-
Ambrosi P, Drici MD, Herpin D, Pathak A 2007 The best of clinical pharmacology in 2006.
Arch. Mal. Coeur. Vaiss. 100 Spec. No. 1: 99-102.
-
Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA 2005 Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome.
Diabetes Res. Clin. Pract. 67: 175-179.
-
Amigo L, Castro J, Miquel JF, Zanlungo S, Young SG, Nervi F 2006 Inactivation of hepatic microsomal triglyceride transfer protein protects mice from diet-induced gallstones.
Gastroenterology 131: 1870-1878.
*
-
An S, Jang YS, Park JS, Kwon BM, Paik YK, Jeong TS 2008 Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes.
Exp. Mol. Med. 40: 407-417.
*
-
Anand PK, Kaul D 2005 Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages.
FEMS Microbiol. Lett. 250: 137-144.
*
-
Anandan R, Mathew S, Sankar TV, Viswanathan Nair PG 2007 Protective effect of n-3 polyunsaturated fatty acids concentrate on isoproterenol-induced myocardial infarction in rats.
Prostaglandins Leukot. Essent. Fatty Acids 76: 153-158.
*
-
Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB 2007 Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
J. Med. Virol. 80: 209-216.
-
Anderson HA, Hiltbold EM, Roche PA 2000 Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation.
Nat. Immunol. 1: 156-162.
*
-
Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC 2004 Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in mouse liver.
Mol. Pharmacol. 66: 1440-1452.
*
-
Andersson S, Gustafsson N, Warner M, Gustafsson JA 2005 Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice.
Proc. Natl. Acad. Sci. U.S.A. 102: 3857-3862.
*
-
Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A 2004 Effects of pravastatin on the expression of ATP-binding cassette transporter A1.
J. Pharmacol. Exp. Ther. 311: 420-425.
*
-
Ange-van Heugten KD, Burns R, Verstegen MW, Jansen WL, Ferket PR, van Heugten E 2007 Evaluation of diabetes determinants in woolly monkeys (Lagothrix lagotricha).
J. Anim. Physiol. Anim. Nutr. (Berl.) 91: 481-491.
*
-
Angelin B, Eriksson M, Parini P, Rudling M 2004 Bile acids and lipoproteins.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19. *
-
Angelin B, Ewerth S, Einarsson K 1983 Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
J. Lipid Res. 24: 461-468.
*
-
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease.
Curr. Gastroenterol. Rep. 4: 37-44.
-
Angulo P 2003 Non-alcoholic steatohepatitis.
Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19. *
-
Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, Alrefai WA 2008 Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts.
Am. J. Physiol. Gastrointest. Liver Physiol. 294: G489-G497.
*
-
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, Baldini M, Delle Volpe A, Lambertenghi Deliliers G 2008 Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation.
Bone Marrow Transplant. 41: 797-804.
-
Annilo T, Tammur J, Hutchinson A, Rzhetsky A, Dean M, Allikmets R 2001 Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4.
Cytogenet. Cell. Genet. 94: 196-201.
-
Antsaklis G, Lewin MR, Sutor DJ, Cowie AG, Clark CG 1975 Gallbladder function, cholesterol stones, and bile composition.
Gut 16: 937-942.
*
-
Appel LJ 2005 Dietary approaches to reduce blood pressure.
J. Anim. Physiol. Anim. Nutr. (Berl.) 89: 433.
*
-
Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K 2006 Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
J. Immunol. 177: 3028-3034.
*
-
Arakawa T, Kita Y, Niikura T 2008 A rescue factor for Alzheimer's diseases: discovery, activity, structure, and mechanism.
Curr. Med. Chem. 15: 2086-2098.
-
Aravindhan K, Webb CL, Jaye M, Ghosh A, Willette RN, Dinardo NJ, Jucker BM 2006 Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study.
J. Lipid Res. 47: 1250-1260.
*
-
Archer A, Lauter G, Hauptmann G, Mode A, Gustafsson JA 2008 Transcriptional activity and developmental expression of liver X receptor (lxr) in zebrafish.
Dev. Dyn. 237: 1090-1098.
-
Argo CK, Loria P, Caldwell SH, Lonardo A 2008 Statins in liver disease: a molehill, an iceberg, or neither?
Hepatology 48: 662-669.
-
Arias-Vasquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, van Duijn CM 2007 The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease.
Neurogenetics 8: 189-193.
-
Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E 2007 Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Ren. Fail. 29: 713-719.
-
Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; the Swiss HIV Cohort Study 2007 Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Pharmacogenet. Genomics 17: 755-764.
-
Arnon R, Yoshimura T, Reiss A, Budai K, Lefkowitch JH, Javitt NB 1998 Cholesterol 7-hydroxylase knockout mouse: a model for monohydroxy bile acid-related neonatal cholestasis.
Gastroenterology 115: 1223-1228.
*
-
Arrese M, Miquel JF, Ananthanarayanan M 2006 BetaKlotho: a new kid on the bile acid biosynthesis block.
Hepatology 43: 191-193.
*
-
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A 2002 Effects of duodenal seal oil administration in patients with inflammatory bowel disease.
Lipids 37: 935-940.
-
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254.
-
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M 2008 Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Bioorg. Med. Chem. 16: 981-994.
*
-
Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP 2008 Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?
Expert Opin. Investig. Drugs 17: 969-972.
-
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG 1997 Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Am. J. Cardiol. 80: 608-613.
*
-
Attaran M, Schneider A, Grote C, Zwiens C, Flemming P, Gratz KF, Jochheim A, Bahr MJ, Manns MP, Ott M 2004 Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits.
J. Hepatol. 41: 837-844.
*
-
Attie AD, Flowers MT, Flowers JB, Groen AK, Kuipers F, Ntambi JM 2007 Stearoyl-CoA desaturase deficiency, hypercholesterolaemia, cholestasis and diabetes.
Novartis Found. Symp. 286: 47-53.
-
Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, Pierce GN 2008 Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
J. Am. Coll. Nutr. 27: 214-221.
-
Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A 2006 A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPARgamma-dependent pathway.
Mol. Endocrinol. 20: 3165-3178.
*
-
Avezov SA, Mansurov FKh 2004 Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis.
Klin. Med. (Mosk.) 82: 55-58.
-
Avezov SA, Mansurova FKh 2004 Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis.
Klin. Med. (Mosk.) 82: 46-49.
-
Axelson M 2004 Studies on biosynthetic pathways to bile acids in human liver cells.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 22. June 18-19. *
-
Axelson M, Mork B, Everson GT 1991 Bile acid synthesis in cultured human hepatoblastoma cells.
J. Biol. Chem. 266: 17770-17777.
*
-
Ayaki Y, Kok E, Javitt NB 1989 Cholic acid synthesis from 26-hydroxycholesterol and 3-hydroxy-5-cholestenoic acid in the rabbit.
J. Biol. Chem. 264: 3818-3821.
*
-
Ayaori M, Sawada S, Yonemura A, Iwamoto N, Ogura M, Tanaka N, Nakaya K, Kusuhara M, Nakamura H, Ohsuzu F 2006 Glucocorticoid receptor regulates ATP-binding cassette transporter-A1 expression and apolipoprotein-mediated cholesterol efflux from macrophages.
Arterioscler. Thromb. Vasc. Biol. 26: 163-168.
*
-
Azambuja MI 2008 Connections: can the 20th century coronary heart disease epidemic reveal something about the 1918 influenza lethality?
Braz. J. Med. Biol. Res. 41: 1-4.
*
-
Aziz A, Xiao CW, Cockell KA, Sarwar Gilani G, Cruz-Hernandez C, Nimal Ratnayake WM 2008 Impact of dietary protein on lipid metabolism in hamsters is source-dependent and associated with changes in hepatic gene expression.
Br. J. Nutr. 100: 503-511.
*
-
Baba MI, Kaul D, Grover A 2006 Importance of blood cellular genomic profile in coronary heart disease.
J. Biomed. Sci. 13: 17-26.
*
-
Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, Sambucetti L 2004 PXR and the regulation of apoA1 and HDL-cholesterol in rodents.
Pharmacol. Res. 50: 237-246.
*
-
Bachs L, Pares A, Elena M, Piera C, Rodes J 1992 Effects of long-term rifampicin administration in primary biliary cirrhosis.
Gastroenterology 102: 2077-2080.
-
Backes JM, Gibson CA, Howard PA 2005 Optimal lipid modification: the rationale for combination therapy.
Vasc. Health Risk Manag. 1: 317-331.
-
Backes JM, Gibson CA, Ruisinger JF, Moriarty PM 2007 Fibrates: what have we learned in the past 40 years?
Pharmacotherapy 27: 412-424.
-
Bai D, Brar P, Holleran S, Ramakrishnan R, Green P 2005 Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men.
Scand. J. Gastroenterol. 40: 183-187.
*
-
Balan V, Dickson ER, Jorgensen RA, Lindor KD 1994 Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis.
Mayo Clin. Proc. 69: 923-929.
-
Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M 2005 Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260.
*
-
Balcerzyk A, Zak I, Krauze J 2007 Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease.
Acta Cardiol. 62: 233-238.
-
Balcerzyk A, Zak I, Krauze J 2007 Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease.
Arch. Med. Res. 38: 545-550.
-
Baldan A, Tarr P, Lee R, Edwards PA 2006 ATP-binding cassette transporter G1 and lipid homeostasis.
Curr. Opin. Lipidol. 17: 227-232.
-
Balistreri WF 2003 Genetic liver disease.
54th Annual Meeting of the American Association for the Study of Liver Diseases.
-
Balistreri WF 1997 Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid.
J. Pediatr. Gastroenterol. Nutr. 24: 573-589.
-
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J 2006 Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
Atherosclerosis 189: 19-30.
-
Balkova K, Gbelska Y 2007 ABC transporter proteins in multidrug resistance of microorganisms.
Epidemiol. Mikrobiol. Imunol. 56: 129-139.
-
Ballatori N, Fang F, Christian WV, Li N, Hammond CL 2008 Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver.
Am. J. Physiol. Gastrointest. Liver Physiol. 295: G179-G186.
*
-
Balmer M, Dufour J 2008 Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated.
Swiss Med. Wkly. 138: 415-419.
*
-
Banerjee A, Hussainzada N, Khandelwal A, Swaan PW 2008 Electrostatic and potential cation-pi forces may guide the interaction of extracellular loop III with Na+ and bile acids for human apical Na+-dependent bile acid transporter.
Biochem. J. 410: 391-400.
*
-
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B 2003 Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.
J. Biol. Chem. 278: 32852-32860.
*
-
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B 2002 Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
Arterioscler. Thromb. Vasc. Biol. 22: 717-726.
*
-
Barbosa FA, de Labio RW, de Oliveira S Rigolin V, Minett T, Bertolucci PH, de Arruda Cardoso Smith M, Payao SL 2006 Apolipoprotein A-V gene polymorphism -1131T>C and Alzheimer's disease.
J. Alzheimers Dis. 10: 365-369.
-
Barcelo-Coblijn G, Collison LW, Jolly CA, Murphy EJ 2005 Dietary alpha-linolenic acid increases brain but not heart and liver docosahexaenoic acid levels.
Lipids 40: 787-798.
-
Barcelo-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ 2007 Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice.
J. Neurochem. 101: 132-141.
-
Barnes DS 2002 Intrahepatic cholestatic liver disease.
http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
-
Barre DE 2007 The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review.
J. Oleo. Sci. 56: 319-325.
*
-
Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ 1993 Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests.
Br. J. Dermatol. 129: 704-707.
-
Baruch Y, Brook JG, Eidelman S, Aviram M 1984 Increased concentration of high density lipoprotein in plasma and decreased platelet aggregation in primary biliary cirrhosis.
Atherosclerosis 53: 151-162.
-
Basso F, Freeman LA, Ko C, Joyce C, Amar MJ, Shamburek RD, Tansey T, Thomas F, Wu J, Paigen B, Remaley AT, Santamarina-Fojo S, Brewer HB Jr 2007 Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited.
J. Lipid Res. 48: 114-126.
*
-
Basu A, Devaraj S, Jialal I 2006 Dietary factors that promote or retard inflammation.
Arterioscler. Thromb. Vasc. Biol. 26: 995-1001.
*
-
Bate C, Marshall V, Colombo L, Diomede L, Salmona M, Williams A 2008 Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta(1-42).
Neuropharmacology 54: 934-943.
-
Bate C, Tayebi M, Diomede L, Salmona M, Williams A 2008 Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells.
BMC Biol. 6: 39.
*
-
Bateson MC, Hill A, Bouchier IA 1980 Analysis of response to ursodeoxycholic acid for gallstone dissolution.
Digestion 20: 358-364.
-
Bateson MC, Ross PE, Murison J, Bouchier IA 1997 Effect of prolonged feeding with chenodeoxycholic acid on bile in patients with and without gallstones.
Gut 18: 599-605.
*
-
Bateson MC, Ross PE, Murison J, Saunders JH, Bouchier IA 1980 Ursodeoxycholic acid therapy and biliary lipids - a dose-response study.
Gut 21: 305-310.
*
-
Battochio AP, Sartori MS, Coelho CA 2005 Water-soluble extract of Coleus barbatus modulates weight gain, energy utilization and lipid metabolism in secondary biliary cirrhosis: an experimental study in young rats.
Acta Cir. Bras. 20: 229-236.
-
Bayliss M, Somers G 2004 Isolation and culture of human hepatocytes.
Methods Mol. Med. 107: 249-268.
-
Bays H 2006 Clinical overview of omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Am. J. Cardiol. 98: S71-S76.
*
-
Beattie AD, Sherlock S 1976 Ascorbic acid deficiency in liver disease.
Gut 17: 571-575.
*
-
Bedu E, Wahli W, Desvergne B 2005 Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Expert Opin. Ther. Targets 9: 861-873.
-
Bell Iii TA, Kelley K, Wilson MD, Sawyer JK, Rudel LL 2007 Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice.
Arterioscler. Thromb. Vasc. Biol. 27: 1396-1402.
-
Bellentani S 2005 Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?
Eur. J. Gastroenterol. Hepatol. 17: 137-140.
*
-
Belli DC, Fournier LA, Lepage G, Yousef I, Roy CC 1994 S-Adenosylmethionine prevents total parenteral nutrition-induced cholestasis in the rat.
J. Hepatol. 21: 18-23.
-
Bellosta S, Bernini F 2005 Modulation of macrophage function and metabolism.
Handb. Exp. Pharmacol. 170: 665-695.
-
Ben-Ari Z, Schafer Z, Sulkes J, Manhaim V, Tur-Kaspa R, Fainaru M 2002 Alterations in serum leptin in chronic liver disease.
Dig. Dis. Sci. 47: 183-189.
*
-
Ben-Ari Z, Tur-Kaspa R, Schafer Z, Baruch Y, Sulkes J, Atzmon O, Greenberg A, Levi N, Fainaru M 2001 Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease.
J. Investig. Med. 49: 325-329.
-
Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A 1998 Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts.
Am. J. Clin. Nutr. 67: 912-918.
*
-
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M 2008 PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2.
Physiol. Res. 57 Suppl. 1: S77-S90.
-
Benito P, Caballero J, Moreno J, Gutierrez-Alcantara C, Munoz C, Rojo G, Garcia S, Soriguer FC 2006 Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome.
Clin. Nutr. 25: 581-587.
-
Bennett DJ, Cooke AJ, Edwards AS 2006 Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis.
Recent Patents Cardiovasc. Drug Discov. 1: 21-46.
-
Benno P, Leijonmarck CE, Monsen U, Uribe A, Midtvedt T 1993 Functional alterations of the microflora in patients with ulcerative colitis.
Scand. J. Gastroenterol. 28: 839-844.
-
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P 2008 LXR signaling couples sterol metabolism to proliferation in the acquired immune response.
Cell 134: 97-111.
*
-
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G 2003 Involvement of retinoid X receptor alpha in coenzyme Q metabolism.
J. Mol. Biol. 326: 795-803.
*
-
Benton JL, Ding J, Tsai MY, Shea S, Rotter JI, Burke GL, Post W 2007 Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis 193: 352-360.
-
Berard AM, Dumon MF, Darmon M 2004 Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion.
FEBS Lett. 559: 125-128.
*
-
Bergasa NV 2005 The pruritus of cholestasis.
J. Hepatol. 43: 1078-1088.
*
-
Bergasa NV 2004 Treatment of the pruritus of cholestasis.
Curr. Treat. Options Gastroenterol. 7: 501-508.
-
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group.
Hepatology 40: 1013-1020.
*
-
Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC 2002 Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.
J. Lipid Res. 43: 486-494.
*
-
Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H 2007 The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies.
Hum. Genet. 121: 169-178.
*
-
Bergheim I, Harsch S, Mueller O, Schimmel S, Fritz P, Stange EF 2006 Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers.
J. Lipid Res. 47: 42-50.
*
-
Berkowitz CM, Shen CS, Bilir BM, Guibert E, Gumucio JJ 1995 Different hepatocytes express the cholesterol 7 alpha-hydroxylase gene during its circadian modulation in vivo.
Hepatology 21: 1658-1667.
-
Bersamin A, Luick BR, King IB, Stern JS, Zidenberg-Cherr S 2008 Westernizing diets influence fat intake, red blood cell fatty acid composition, and health in remote Alaskan native communities in the Center for Alaska Native Health study.
J. Am. Diet. Assoc. 108: 266-273.
-
Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM 2006 Hypertriglyceridemia: management of atherogenic dyslipidemia.
J. Fam. Pract. 55: S1-S8.
-
Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I 2008 SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment.
Exp. Clin. Endocrinol. Diabetes 116: 262-267.
-
Bertok L 2004 Bile acids in physico-chemical host defence.
Pathophysiology 11: 139-145.
-
Bertolotti M, Gabbi C, Anzivino C, Carulli L, Loria P, Carulli N 2008 Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights from evidence on hepatic cholesterol degradation and gallstone disease in humans.
Curr. Med. Chem. 15: 2271-2284.
-
Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N 2007 Age-related changes in bile acid synthesis and hepatic nuclear receptor expression.
Eur. J. Clin. Invest. 37: 501-508.
*
-
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N 2006 Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis.
Eur. J. Clin. Invest. 36: 170-175.
-
Bertolotti M, Zambianchi L, Carulli L, Simonini MS, Del Puppo M, Kienle MG, Loria P, Pinetti A, Carulli N 2003 Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption.
Hepatology 38: 939-946.
*
-
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U 2008 Pharmacological approaches to improve endothelial repair mechanisms.
Expert Rev. Cardiovasc. Ther. 6: 1071-1082.
-
Besnard P, Landrier JF, Grober J, Niot I 2004 Is the ileal bile acid-binding protein (I-BABP) gene involved in cholesterol homeostasis?
Med. Sci. (Paris) 20: 73-77.
-
Betteridge DJ 2001 Lipid-lowering trials in diabetes.
Curr. Opin. Lipidol. 12: 619-623.
-
Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F 1996 Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport.
J. Hepatol. 24: 343-352.
*
-
Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW 2007 Selective up-regulation of LXR-regulated genes ABCA1, ABCG1 and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol.
J. Biol. Chem. 282: 5207-5216.
*
-
Beyer TP, Chen Y, Porter RK, Lu D, Schmidt RJ, Mantlo NB, Konrad RJ, Cao G 2008 Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein.
Lipids 43: 611-618.
-
Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G 2004 Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
J. Pharmacol. Exp. Ther. 309: 861-868.
*
-
Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK 2004 Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: functional implications in hepatic cholesterol and glucose metabolism.
J. Biol. Chem. 279: 45139-45147.
*
-
Bhat B, Esau C, Davis S, Propp S, Kinberger G, Gaus H, Freier S, Swayze EE, Bennett CF 2008 2'-O-Methoxyethyl/2'-fluoro modified oligonucleotides result in more potent inhibition of micro RNA-122 in vivo: a target implicated in HCV replication.
Nucleic Acids Symp. Ser. (Oxf.) 52: 69.
-
Bickler SW, Demaio A 2008 Western diseases: current concepts and implications for pediatric surgery research and practice.
Pediatr. Surg. Int. 24: 251-255.
-
Bilhartz LE 1988 Cholesterol gallstone disease: the current status of nonsurgical therapy.
Am. J. Med. Sci. 296: 45-56.
-
Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI 2006 Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.
Am. J. Physiol. Endocrinol. Metab. 290: E716-E722.
*
-
Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK 2000 Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice.
Kidney Int. 57: 129-136.
*
-
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT 2008 Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Neurology Jun 4 [Epub ahead of print].
-
Birrell MA, Catley MC, Hardaker E, Wong S, Willson TM, McCluskie K, Leonard T, Farrow SN, Collins JL, Haj-Yahia S, Belvisi MG 2007 Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses.
J. Biol. Chem. 282: 31882-31890.
*
-
Bishop-Bailey D 2004 FXR as a novel therapeutic target for vascular disease.
Drug News Perspect. 17: 499-504.
-
Bishop-Bailey D, Walsh DT, Warner TD 2004 Expression and activation of the farnesoid X receptor in the vasculature.
Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673.
*
-
Bisschop PH, Bandsma RH, Stellaard F, Ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA 2004 Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans.
Am. J. Clin. Nutr. 79: 570-576.
*
-
Bjorkhem I, Araya Z, Rudling M, Angelin B, Einarsson C, Wikvall K 2002 Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1.
J. Biol. Chem. 277: 26804-26807.
*
-
Bjorkhem I, Meaney S, Heverin M, Andersson U, Axelsson M, Panzenboek U, Sattler W 2006 Role of oxysterols and cholestenoic acids in a crosstalk between the brain and the liver.
Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 23. *
-
Blasi C 2008 The autoimmune origin of atherosclerosis.
Atherosclerosis May 23 [Epub ahead of print].
-
Blazovics A, Hagymasi K, Pronai L 2004 Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases.
Orv. Hetil. 145: 2523-2529.
-
Bleie O, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygard OK 2007 Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
J. Intern. Med. 262: 244-253.
*
-
Bloch AS 2005 Low carbohydrate diets, pro: time to rethink our current strategies.
Nutr. Clin. Pract. 20: 3-12.
-
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, Hudes ML 2007 Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study.
Nutr. J. 6: 30.
*
-
Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F 2004 Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes.
Diabetologia 47: 104-112.
*
-
Bloomer JR, Boyer JL 1975 Phenobarbital effects in cholestatic liver diseases.
Ann. Intern. Med. 82: 310-317.
-
Blum HE 2006 Gene therapy for liver diseases: experimental strategies.
Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 44-45. *
-
Boadu E, Choi HY, Lee DW, Waddington EI, Chan T, Asztalos B, Vance JE, Chan A, Castro G, Francis GA 2006 Correction of apolipoprotein A-I-mediated lipid efflux and HDL particle formation in human Niemann-Pick type C disease fibroblasts.
J. Biol. Chem. 281: 37081-37090.
*
-
Bocher V, Pineda-Torra I, Fruchart JC, Staels B 2002 PPARs: transcription factors controlling lipid and lipoprotein metabolism.
Ann. N. Y. Acad. Sci. 967: 7-18.
-
Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G 2007 Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function.
World J. Gastroenterol. 13: 5217-5225.
*
-
Bodin K 2004 Role of CYP3A4 as a cholesterol and bile acid metabolizing enzyme.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 25. June 18-19. *
-
Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Bjorkhem I, Diczfalusy U 2002 Metabolism of 4 beta -hydroxycholesterol in humans.
J. Biol. Chem. 277: 31534-31540.
*
-
Bodolay E, Seres I, Szodoray P, Csipo I, Jakab Z, Vegh J, Szilagyi A, Szegedi G, Paragh G 2008 Evaluation of paraoxonase activity in patients with mixed connective tissue disease.
J. Rheumatol. 35: 237-243.
-
Bodor ET, Offermanns S 2008 Nicotinic acid: an old drug with a promising future.
Br. J. Pharmacol. 153 Suppl. 1: S68-S75.
*
-
Bogdanovic M, Bulat P 2008 Biliary function in workers occupationally exposed to aluminium dust and fumes.
Arh. Hig. Rada. Toksikol. 59: 135-139.
-
Bohan A, Chen WS, Denson LA, Held MA, Boyer JL 2003 Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis.
J. Biol. Chem. 278: 36688-36698.
*
-
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP 2005 Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Liver Transpl. 11: 61-67.
*
-
Boland B, Beguin C, Zech F, Desager JP, Lambert M 2001 Serum beta-carotene in anorexia nervosa patients: a case-control study.
Int. J. Eat. Disord. 30: 299-305.
-
Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, Wichmann HE, Koenig W, Kolb H, Herder C 2005 Genetics of type 2 diabetes: impact of interleukin-6 gene variants.
Gesundheitswesen 67 Suppl. 1: 122-126.
-
Bookman ID, Pham J, Guindi M, Heathcote EJ 2006 Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins.
Liver Int. 26: 566-571.
*
-
Borba EF, Carvalho JF, Bonfa E 2006 Mechanisms of dyslipoproteinemias in systemic lupus erythematosus.
Clin. Dev. Immunol. 13: 203-208.
-
Bordoni A, Di Nunzio M, Danesi F, Biagi PL 2006 Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors.
Genes & Nutrition 1: 95-106. *
-
Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BH, Groen AK, van Tol A, Dullaart RP 2008 The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin:cholesterol acyltransferase activity.
Biochim. Biophys. Acta 1781: 10-15.
*
-
Borst P, Zelcer N, van Helvoort A 2000 ABC transporters in lipid transport.
Biochim. Biophys. Acta 1486: 128-144.
*
-
Borthwick L; on behalf of the UK Study Group 1998 The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia.
Clin. Drug Investig. 15: 397-404.
-
Bosch T 2005 Therapeutic apheresis - state of the art in the year 2005.
Ther. Apher. Dial. 9: 459-468.
*
-
Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I 2005 Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP.
EMBO J. 24: 2624-2633.
*
-
Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B 1996 Byler-like familial cholestasis in an extended kindred.
Arch. Dis. Child. 75: 223-227.
-
Bourre JM, Galea F 2006 An important source of omega-3 fatty acids, vitamins D and E, carotenoids, iodine and selenium: a new natural multi-enriched egg.
J. Nutr. Health Aging 10: 371-376.
-
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P 2004 Sigma receptor ligands: applications in inflammation and oncology.
Curr. Opin. Investig. Drugs 5: 1158-1163.
-
Bowden K, Ridgway ND 2008 OSBP negatively regulates ABCA1 protein stability.
J. Biol. Chem. 283: 18210-18217.
*
-
Boyer JL 2005 Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?
Gastroenterology 129: 735-740.
*
-
Boyer JL 2007 New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.
J. Hepatol. 46: 365-371.
*
-
Boyle PJ 2007 Diabetes mellitus and macrovascular disease: mechanisms and mediators.
Am. J. Med. 120: S12-S17.
*
-
Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, Lusis AJ, Collins A, Hseuh WA, Collins JL, Tangirala RK, Tontonoz P 2007 Ligand activation of LXRbeta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRalpha and apoE.
J. Clin. Invest. 117: 2337-2346.
*
-
Braga MF, Grace MG, Lenis J, Kennedy FP, Teplinsky AL, Roederer G, Palumbo PJ, Colin P, Leiter LA 2008 Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial.
Atherosclerosis Aug 12 [Epub ahead of print].
-
Brailski Kh, Damianov B 1983 Primary biliary cirrhosis.
Vutr. Boles. 22: 27-37.
-
Bramlett KS, Yao S, Burris TP 2000 Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids.
Mol. Genet. Metab. 71: 609-615.
*
-
Branten AJ, Swinkels DW, Klasen IS, Wetzels JF 2004 Serum ferritin levels are increased in patients with glomerular diseases and proteinuria.
Nephrol. Dial. Transplant. 19: 2754-2760.
*
-
Brar P, Kwon GY, Holleran S, Bai D, Tall AR, Ramakrishnan R, Green PH 2006 Change in lipid profile in celiac disease: beneficial effect of gluten-free diet.
Am. J. Med. 119: 786-790.
*
-
Bravo E, Napolitano M, Lopez-Soldado I, Valeri M, Botham KM, Stefanutti C 2006 Hypercholesterolaemia alters the responses of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil.
Eur. J. Clin. Invest. 36: 788-795.
*
-
Bravo I, Amigo L, Cohen DE, Nervi F, Rigotti A, Francone O, Zanlungo S 2007 Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse.
Biochim. Biophys. Acta 1770: 979-988.
*
-
Brenol CV, Monticielo OA, Xavier RM, Brenol JC 2007 Rheumatoid arthritis and atherosclerosis.
Rev. Assoc. Med. Bras. 53: 465-470.
-
Brewer HB Jr, Santamarina-Fojo S 2003 New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport.
Am. J. Cardiol. 91: 3E-11E.
*
-
Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, Thorpe SR, Baynes JW 2008 Increased methionine sulfoxide content of ApoAI in type 1 diabetes.
J. Lipid Res. 49: 847-855.
*
-
Brousseau ME 2003 Statins, super-statins and cholesterol absorption inhibitors.
IDrugs 6: 458-463.
-
Brousseau ME 2003 ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption.
Curr. Opin. Lipidol. 14: 35-40.
-
Brousseau ME, Hoeg JM 1999 Transgenic rabbits as models for atherosclerosis research.
J. Lipid Res. 40: 365-375.
*
-
Brousseau ME, Schaefer EJ 2002 New targets for medical treatment of lipid disorders.
Curr. Atheroscler. Rep. 4: 343-349.
-
Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr, Gu JZ 2000 Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds.
J. Lipid Res. 41: 433-441.
*
-
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ 2004 Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
N. Engl. J. Med. 350: 1505-1515.
*
-
Brouwers A, Langlois M, Delanghe J, Billiet J, De Buyzere M, Vercaemst R, Rietzschel E, Bernard D, Blaton V 2004 Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism.
Atherosclerosis 176: 189-195.
-
Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B 2004 Differential expression of cholesterol hydroxylases in Alzheimer's disease.
J. Biol. Chem. 279: 34674-34681.
*
-
Bruemmer D, Law RE 2005 Liver X receptors: potential novel targets in cardiovascular diseases.
Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 533-540.
-
Bruinsma KA, Taren DL 2000 Dieting, essential fatty acid intake, and depression.
Nutr. Rev. 58: 98-108.
-
Brumeanu TD, Goldstein R, Casares S 2006 Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors.
Clin. Immunol. 119: 1-12.
*
-
Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR 2006 Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.
J. Clin. Invest. 116: 1052-1062.
*
-
Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR 2006 Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.
Circ. Res. 99: 672-674.
*
-
Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR 2007 beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment.
Nat. Med. 13: 340-347.
*
-
Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR 2005 Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene.
PLoS Genet. 1: e83.
*
-
Brunner J, Parhofer KG, Schwandt P, Bronisch T 2002 Cholesterol, essential fatty acids, and suicide.
Pharmacopsychiatry 35: 1-5.
-
Brunser O, Gotteland M, Cruchet S 2007 Functional fermented milk products.
Nestle Nutr. Workshop Ser. Pediatr. Program 60: 235-250.
-
Brydges S, Kastner DL 2006 The systemic autoinflammatory diseases: inborn errors of the innate immune system.
Curr. Top. Microbiol. Immunol. 305: 127-160.
-
Bryhn M, Hansteen H, Schanche T, Aakre SE 2006 The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.
Prostaglandins Leukot. Essent. Fatty Acids 75: 19-24.
*
-
Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bassmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Holl C, Seeger M, Elsharawy A, Lu T, Egberts J, Fandrich F, Folsch UR, Krawczak M, et al 2007 A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.
Nat. Genet. 39: 995-999.
*
-
Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ 2002 In primary sclerosing cholangitis, gallbladder polyps are frequently malignant.
Am. J. Gastroenterol. 97: 1138-1142.
*
-
Buettner C, Phillips RS, Davis RB, Gardiner P, Mittleman MA 2007 Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks.
Am. J. Cardiol. 99: 661-666.
*
-
Bultel S, Helin L, Clavey V, Chinetti-Gbaguidi G, Rigamonti E, Colin M, Fruchart JC, Staels B, Lestavel S 2008 Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages.
Arterioscler. Thromb. Vasc. Biol. Sep 18 [Epub ahead of print].
-
Buono C, Li Y, Waldo SW, Kruth HS 2007 Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL.
J. Lipid Res. 48: 2411-2418.
*
-
Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P 2007 Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis.
Transl. Res. 150: 101-105.
*
-
Buraczynska M, Swatowski A, Buraczynska K, Dragan M, Ksiazek A 2008 Heat-shock protein gene polymorphisms and the risk of nephropathy in type 2 diabetes patients.
Clin. Sci. (Lond.) May 30 [Epub ahead of print].
-
Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, Stukas S, Theroux L, Chan JY, Donkin J, Wilkinson A, Balik D, Christie B, Poirier J, Lutjohann D, Demattos RB, Wellington CL 2008 ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo.
J. Lipid Res. 49: 1254-1267.
*
-
Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL 2005 Phosphatidylinositol raises HDL-C levels in humans.
J. Lipid Res. 46: 350-355.
*
-
Burnett JR, Huff MW 2006 Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.
Expert Opin. Investig. Drugs 15: 1337-1351.
-
Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW 2006 The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo.
J. Neurochem. 98: 792-800.
*
-
Burns T, Maciejewski SR, Hamilton WR, Zheng M, Mooss AN, Hilleman DE 2007 Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Pharmacotherapy 27: 633-638.
-
Burris TP, Eacho PI, Cao G 2002 Genetic disorders associated with ATP binding cassette cholesterol transporters.
Mol. Genet. Metab. 77: 13-20.
*
-
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA 2005 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Clin. Ther. 27: 1181-1195.
*
-
Buters JT, Zysset T, Reichen J 1993 Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.
Biochem. Pharmacol. 46: 983-991.
-
Butt MS, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS 2008 Oat: unique among the cereals.
Eur. J. Nutr. 47: 68-79.
*
-
Buysschaert M, Tomasi JP, Hermans MP 2005 Prospective screening for biopsy proven coeliac disease, autoimmunity and malabsorption markers in Belgian subjects with type 1 diabetes.
Diabet. Med. 22: 889-892.
*
-
Caballeria L, Pares A, Rodes J 1999 Treatment of primary biliary cirrhosis.
Contributions to Science 1: 79-85. *
-
Cabezas Gelabert R 2004 Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial.
Rev. Clin. Esp. 204: 632-635.
-
Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, Vazquez-Carrera M 2005 Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages.
Mol. Cell. Biochem. 275: 173-179.
*
-
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV 2003 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Metabolism 52: 652-657.
*
-
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC 2007 Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Atherosclerosis 195: 17-22.
-
Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F 2008 New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism.
Atherosclerosis Jul 6 [Epub ahead of print].
-
Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC 2008 Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ATP-binding cassette (ABC) G5/G8.
J. Lipid Res. 49: 1904-1911.
*
-
Campana G, Pasini P, Roda A, Spampinato S 2005 Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Biochem. Pharmacol. 69: 1755-1763.
*
-
Campbell IW 2005 The clinical significance of PPAR gamma agonism.
Curr. Mol. Med. 5: 349-363.
-
Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, Santos K, Crispim D, Roisemberg I, Krolewski AS, Gross JL 2005 The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes.
Diabetes 54: 3326-3330.
*
-
Caniato RN, Alvarenga ME, Garcia-Alcaraz MA 2006 Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine.
Aust. N. Z. J. Psychiatry 40: 691-697.
*
-
Canton RF, Peijnenburg AA, Hoogenboom RL, Piersma AH, van der Ven LT, van den Berg M, Heneweer M 2008 Subacute effects of hexabromocyclododecane (HBCD) on hepatic gene expression profiles in rats.
Toxicol. Appl. Pharmacol. 231: 267-272.
*
-
Cantwell MM, Flynn MA, Gibney MJ 2006 Acute postprandial effect of hydrogenated fish oil, palm oil and lard on plasma cholesterol, triacylglycerol and non-esterified fatty acid metabolism in normocholesterolaemic males.
Br. J. Nutr. 95: 787-794.
*
-
Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI 2007 Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2.
Infect. Immun. 75: 753-759.
*
-
Cao G, Bales KR, Demattos RB, Paul SM 2007 Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics.
Curr. Alzheimer Res. 4: 179-184.
-
Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC 2002 Phospholipid transfer protein is regulated by liver X receptors in vivo.
J. Biol. Chem. 277: 39561-39565.
*
-
Cao G, Liang Y, Jiang XC, Eacho PI 2004 Liver X receptors as potential therapeutic targets for multiple diseases.
Drug News Perspect. 17: 35-41.
-
Cao WM, Murao K, Imachi H, Yu X, Dobashi H, Yoshida K, Muraoka T, Kotsuna N, Nagao S, Wong NC, Ishida T 2004 Insulin like growth factor-I regulation of hepatic scavenger receptor class BI.
Endocrinology 145: 5540-5547.
*
-
Capell WH, Eckel RH 2005 Severe hypertriglyceridemia with a history of treatment failure.
Nat. Clin. Pract. Endocrinol. Metab. 1: 53-58.
*
-
Capristo E, Addolorato G, Mingrone G, Scarfone A, Greco AV, Gasbarrini G 2000 Low-serum high-density lipoprotein-cholesterol concentration as a sign of celiac disease.
Am. J. Gastroenterol. 95: 3331-3332.
*
-
Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, Bernard O 1995 Liver transplantation in children with Alagille syndrome - a study of twelve cases.
Transplantation 60: 339-342.
-
Carmena R, Betteridge DJ 2004 Statins and diabetes.
Semin. Vasc. Med. 4: 321-332.
-
Carpentier YA, Portois L, Malaisse WJ 2006 n-3 Fatty acids and the metabolic syndrome.
Am. J. Clin. Nutr. 83: 1499S-1504S.
*
-
Carrella M, Roda E 1999 Evolving concepts in the pathophysiology of biliary lipid secretion.
Ital. J. Gastroenterol. Hepatol. 31: 643-648.
-
Carrero JJ, Fonolla J, Marti JL, Jimenez J, Boza JJ, Lopez-Huertas E 2007 Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program.
J. Nutr. 137: 384-390.
*
-
Carter CJ 2007 Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis.
Neurochem. Int. 50: 12-38.
-
Carter CJ 2008 Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades.
Neurochem. Int. 52: 920-934.
-
Carulli N, Loria P, Bertolotti M, Ponz de Leon M, Menozzi D, Medici G, Piccagli I 1984 Effects of acute changes of bile acid pool composition on biliary lipid secretion.
J. Clin. Invest. 74: 614-624.
*
-
Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G, Digrisolo A 1981 Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial.
J. Clin. Pharmacol. 21: 436-442.
-
Carulli N, Ponz De Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P 1980 Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid.
J. Lipid Res. 21: 35-43.
*
-
Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, Napper FL, Sala-Vila A, West AL, Mathers JC, Packard C, Williams CM, Calder PC, Minihane AM 2008 Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study.
Am. J. Clin. Nutr. 88: 618-629.
*
-
Casos K, Saiz MP, Ruiz-Sanz JI, Mitjavila MT 2008 Atherosclerosis prevention by a fish oil-rich diet in apoE(-/-) mice is associated with a reduction of endothelial adhesion molecules.
Atherosclerosis Mar 16 [Epub ahead of print].
-
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC 2003 Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus.
Clin. Drug Investig. 23: 639-650.
-
Castellote J, Ariza J, Rota R, Girbau A, Xiol X 2008 Serious drug-induced liver disease secondary to ezetimibe.
World J. Gastroenterol. 14: 5098-5099.
*
-
Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P 2003 Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism.
Mol. Cell. 12: 805-816.
*
-
Castro IA, Monteiro VC, Barroso LP, Bertolami MC 2007 Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia.
Nutrition 23: 127-137.
*
-
Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F 2007 Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease.
Hepatology 45: 1261-1266.
*
-
Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A 2006 Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1.
Biochim. Biophys. Acta 1761: 655-666.
*
-
Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM 2001 Regulation and activity of the human ABCA1 gene in transgenic mice.
J. Biol. Chem. 276: 18046-18051.
*
-
Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, Wells SJ, Goua M, Wahle KW, Calder PC, Cestaro B 2007 Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects.
Atherosclerosis 193: 159-167.
-
Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ 2008 Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
Transplantation 86: 245-250.
-
Celinska-Lowenhoff M, Undas A 2004 Nonlipid effects of fibrates.
Przegl. Lek. 61: 99-101.
-
Cerf E, Gasper R, Rychnovsky S, Chang XB, Buyse F, Ruysschaert JM 2007 Multidrug resistance protein 1 is not associated to detergent-resistant membranes.
Biochem. Biophys. Res. Commun. 355: 1025-1030.
*
-
Cerkauskiene R, Kaminskas A, Kaltenis P, Vitkus D 2003 Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome.
Medicina (Kaunas) 39 Suppl. 1: 82-87.
-
Ceryak S, Bouscarel B, Malavolti M, Robins SJ, Caslow KL, Fromm H 2000 Effect of ursodeoxycholic acid on hepatic LDL binding and uptake in dietary hypercholesterolemic hamsters.
Atherosclerosis 153: 59-67.
-
Cha JY, Repa JJ 2007 The liver X receptor and hepatic lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR.
J. Biol. Chem. 282: 743-751.
*
-
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF 2005 "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis.
Cell. Metab. 1: 309-322.
*
-
Chan DC, Watts GF, Barrett PH, Whitfield AJ, Van Bockxmeer FM 2004 ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men.
Arterioscler. Thromb. Vasc. Biol. 24: 2188-2191.
*
-
Chan DC, Watts GF, Nguyen MN, Barrett PH 2006 Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Am. J. Clin. Nutr. 84: 37-43.
*
-
Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES 2006 The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women.
Atherosclerosis 187: 309-315.
-
Chang F, Jaber LA, Berlie HD, O'Connell MB 2007 Evolution of peroxisome proliferator-activated receptor agonists.
Ann. Pharmacother. 41: 973-983.
-
Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT 2004 Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation.
J. Lipid Res. 45: 2116-2122.
*
-
Chang SJ, Tsai PC, Chen CJ, Lai HM, Ko YC 2007 The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout.
Rheumatology (Oxford) 46: 1662-1666.
-
Chapidze G E, Kapanadze SD, Dolidze NK, Latsabidze NE, Bakhutashvili ZV 2006 Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis.
Kardiologiia 46: 11-13.
-
Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR 2008 Bioactive dietary long-chain fatty acids: emerging mechanisms of action.
Br. J. Nutr. May 20 [Epub ahead of print].
*
-
Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA 2008 Docosahexaenoic acid alters the size and distribution of cell surface microdomains.
Biochim. Biophys. Acta 1778: 466-471.
*
-
Chapman C, Morgan LM, Murphy MC 2000 Maternal and early dietary fatty acid intake: changes in lipid metabolism and liver enzymes in adult rats.
J. Nutr. 130: 146-151.
*
-
Charoensit P, Kawakami S, Higuchi Y, Hashida M 2008 Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice.
J. Gene Med. 10: 61-69.
-
Chatterjee B, Echchgadda I, Song CS 2005 Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1.
Methods Enzymol. 400: 165-191.
-
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC 2007 Dietary fatty acid intakes and the risk of ovulatory infertility.
Am. J. Clin. Nutr. 85: 231-237.
*
-
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files.
Science 294: 1866-1870.
*
-
Chechi K, Cheema SK 2006 Maternal diet rich in saturated fats has deleterious effects on plasma lipids of mice.
Exp. Clin. Cardol. 11: 129-135.
-
Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S 2005 Lack of stimulation of cholesterol ester transfer protein by cholesterol in the presence of a diet high in monounsaturated fatty acids.
J. Lipid Res. 46: 2356-2366.
*
-
Chen J, Raymond K 2006 Treatment effect of rifampicin on cholestasis.
The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml).
-
Chen M, Li W, Wang N, Zhu Y, Wang X 2007 ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1.
Am. J. Physiol. Cell Physiol. 292: C1493-C1501.
*
-
Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM 2000 Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.
Mol. Ther. 2: 256-261.
-
Chen W, Chiang JY 2003 Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha).
Gene 313: 71-82.
*
-
Chen W, Gluud C 2004 Bile acids for liver transplanted patients.
Cochrane Database Syst. Rev. 2: CD004384. *
-
Chen W, Jump DB, Esselman WJ, Busik JV 2007 Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid.
Invest. Ophthalmol. Vis. Sci. 48: 18-26.
*
-
Chen W, Owsley E, Yang Y, Stroup D, Chiang JY 2001 Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids.
J. Lipid Res. 42: 1402-1412.
*
-
Chen Y, Thelin WR, Yang B, Milgram SL, Jacobson K 2006 Transient anchorage of cross-linked glycosyl-phosphatidylinositol-anchored proteins depends on cholesterol, Src family kinases, caveolin, and phosphoinositides.
J. Cell Biol. 175: 169-178.
*
-
Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ 2008 Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance.
J. Hum. Genet. 53: 757-763.
*
-
Chen ZQ, Annilo T, Shulenin S, Dean M 2004 Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster on mouse chromosome 7F3.
Mamm. Genome 15: 335-343.
*
-
Cheng AY, Leiter LA 2006 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Curr. Opin. Cardiol. 21: 400-404.
-
Cheng JB, Motola DL, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW 2004 Identification and characterization of CYP2R1, a microsomal vitamin D 25-hydroxylase.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 21. June 18-19. *
-
Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, Setchell KD, Russell DW 2003 Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease.
J. Clin. Endocrinol. Metab. 88: 1833-1841.
*
-
Cheng JF, Zapf J, Takedomi K, Fukushima C, Ogiku T, Zhang SH, Yang G, Sakurai N, Barbosa M, Jack R, Xu K 2008 Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators.
J. Med. Chem. 51: 2057-2061.
*
-
Chernev K, Bakalov V 1985 Clinical-dispensary finding of patients with primary biliary cirrhosis.
Vutr. Boles. 24: 42-46.
-
Chevailler A, Saint-Andre JP, Preel JL, Boyer J, Joubaud F, Hurez D 1988 Clinico-immunological profile of hepatic and extrahepatic diseases accompanied by anti-mitochondrial antibodies.
Ann. Med. Interne. (Paris) 139: 19-23.
-
Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L 1996 Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Biochem. J. 314: 781-786.
*
-
Chiang JY 2002 Bile acid regulation of gene expression: roles of nuclear hormone receptors.
Endocr. Rev. 23: 443-463.
*
-
Chiang JY 1998 Regulation of bile acid synthesis.
Front. Biosci. 3: d176-d193.
-
Chiang JY 2004 Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms.
J. Hepatol. 40: 539-551.
*
-
Chiang JY 2003 Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors.
Am. J. Physiol. Gastrointest. Liver Physiol. 284: G349-G356.
*
-
Chiang JY, Kimmel R, Stroup D 2001 Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha).
Gene 262: 257-265.
*
-
Chiang JY, Kimmel R, Weinberger C, Stroup D 2000 Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription.
J. Biol. Chem. 275: 10918-10924.
*
-
Chiang JYL, Li T, Jahan A 2004 Mechanisms of bile acid inhibition of genes in bile acid synthesis.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 23. June 18-19. *
-
Chiba H, Osaka T, Iwasaki N, Suzuki H, Akizawa K, Fujisawa S, Intoh S, Watanabe M, Yoshida J, Matsuno K, et al 1991 Spurious elevation of serum high-density lipoprotein cholesterol in patients with cholestatic liver diseases.
Biochem. Med. Metab. Biol. 46: 329-343.
-
Chinetti G, Fruchart JC, Staels B 2006 Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR.
Biochem. Soc. Trans. 34: 1128-1131.
*
-
Chinetti G, Fruchart JC, Staels B 2003 Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications.
Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45.
-
Chinetti G, Zawadski C, Fruchart JC, Staels B 2004 Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.
Biochem. Biophys. Res. Commun. 314: 151-158.
*
-
Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka AL, Lepore M, Fruchart JC, Clavey V, Ikonen E, Lestavel S, Staels B 2005 Peroxisome proliferator-activated receptor-alpha controls cellular cholesterol trafficking in macrophages.
J. Lipid Res. 46: 2717-2725.
*
-
Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A 2007 Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Atherosclerosis 195: 100-109.
-
Chitturi S, Farrell GC 2001 Drug-induced cholestasis.
Semin. Gastrointest. Dis. 12: 113-124.
-
Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS 2007 Association of metabolic syndrome with proximal and synchronous colorectal neoplasm.
Clin. Gastroenterol. Hepatol. 5: 221-229.
-
Chiu WC, Wang YC, Chien YW, Hou YC, Hu YM, Yeh SL 2008 Effects of dietary fish oil supplementation on cellular adhesion molecule expression and tissue myeloperoxidase activity in hypercholesterolemic mice with sepsis.
J. Nutr. Biochem. Jul 3 [Epub ahead of print].
*
-
Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB 2007 Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis.
Diabetes 56: 1534-1543.
*
-
Choi BG, Vilahur G, Viles-Gonzalez JF, Badimon JJ 2006 The role of high-density lipoprotein cholesterol in atherothrombosis.
Mt. Sinai J. Med. 73: 690-701.
*
-
Choi EM 2007 Oxidative status of DBA/1J mice with type II collagen-induced arthritis.
J. Appl. Toxicol. 27: 472-481.
*
-
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ 2005 In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid.
J. Med. Food 8: 348-352.
-
Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, Redinbo MR 2005 Structural disorder in the complex of human PXR and the macrolide antibiotic rifampicin.
Mol. Endocrinol. 19: 1125-1134.
*
-
Christenson LK, McAllister JM, Martin KO, Javitt NB, Osborne TF, Strauss JF 3rd 1998 Oxysterol regulation of steroidogenic acute regulatory protein gene expression. Structural specificity and transcriptional and posttranscriptional actions.
J. Biol. Chem. 273: 30729-30735.
*
-
Chu K, Miyazaki M, Man WC, Ntambi JM 2006 Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation.
Mol. Cell. Biol. 26: 6786-6798.
*
-
Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM 2007 High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors.
Ann. Rheum. Dis. 66: 208-214.
*
-
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM 2007 Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
J. Rheumatol. 34: 1849-1854.
-
Chuu CP, Kokontis JM, Hiipakka RA, Liao S 2007 Modulation of liver X receptor signaling as novel therapy for prostate cancer.
J. Biomed. Sci. 14: 543-553.
*
-
Ciacci C, Cirillo M, Cavallaro R, Mazzacca G 2002 Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage.
Digestion 66: 178-185.
-
Cigliano L, Maresca B, Salvatore A, Nino M, Monfrecola G, Ayala F, Carlucci A, Pugliese RC, Pedone C, Abrescia P 2008 Haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting lecithin-cholesterol acyltransferase activity.
J. Eur. Acad. Dermatol. Venereol. 22: 417-425.
*
-
Cignarella A, Bellosta S, Corsini A, Bolego C 2006 Hypolipidemic therapy for the metabolic syndrome.
Pharmacol. Res. 53: 492-500.
*
-
Cignarella A, Engel T, Eckardstein A, Kratz M, Lorkowski S, Lueken A, Assmann G, Cullen P 2005 Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors.
Atherosclerosis 179: 229-236.
-
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S 2007 Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.
BMC Gastroenterol. 7: 44.
*
-
Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G 2005 Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process.
Gastroenterology 128: 1258-1267.
*
-
Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P 1989 Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus.
Kidney Int. 36: 653-660.
-
Clarke GA, Bouchard G, Paigen B, Carey MC 2004 Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.
Gut 53: 136-142.
*
-
Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J 2001 Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.
Proc. Natl. Acad. Sci. U.S.A. 98: 2610-2615.
*
-
Claudel T, Staels B, Kuipers F 2005 The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030.
*
-
Claudel T, Sturm E, Kuipers F, Staels B 2004 The farnesoid X receptor: a novel drug target?
Expert Opin. Investig. Drugs 13: 1135-1148.
-
Clayton PT 1991 Inborn errors of bile acid metabolism.
J. Inherit. Metab. Dis. 14: 478-496.
-
Clayton PT 2006 Hereditary liver diseases: screening strategies.
Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 42-43. *
-
Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG 1996 Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.
Gut 38: 623-628.
*
-
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH 2004 Multiple rare alleles contribute to low plasma levels of HDL cholesterol.
Science 305: 869-872.
*
-
Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F 1985 Role of plasmapheresis in primary biliary cirrhosis.
Gut 26: 291-294.
*
-
Cohran VC, Heubi JE 2003 Treatment of pediatric cholestatic liver disease.
Curr. Treat. Options Gastroenterol. 6: 403-415.
-
Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, Bacchi-Reggiani ML, Roda E, Festi D 2006 Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients.
World J. Gastroenterol. 12: 5336-5343.
*
-
Colin A, Reggers J, Castronovo V, Ansseau M 2003 Lipids, depression and suicide.
Encephale 29: 49-58.
-
Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P 2008 Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Endocrinology Jun 19 [Epub ahead of print].
*
-
Collins JL 2004 Therapeutic opportunities for liver X receptor modulators.
Curr. Opin. Drug Discov. Devel. 7: 692-702.
-
Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM 2002 Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.
J. Med. Chem. 45: 1963-1966.
*
-
Conchillo A, Valencia I, Puente A, Ansorena D, Astiasaran I 2006 Functional components in fish and algae oils.
Nutr. Hosp. 21: 369-373.
-
Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF 2007 Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers.
Psychiatry Res. 152: 1-10.
-
Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF 2007 High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism.
Psychosom. Med. 69: 932-934.
-
Cooper AD, Craig WY, Taniguchi T, Everson GT 1994 Characteristics and regulation of bile salt synthesis and secretion by human hepatoma HepG2 cells.
Hepatology 20: 1522-1531.
-
Corey DA, Kelley TJ 2007 Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts.
Biochim. Biophys. Acta 1772: 748-754.
*
-
Cornwell PD, De Souza AT, Ulrich RG 2004 Profiling of hepatic gene expression in rats treated with fibric acid analogs.
Mutat. Res. 549: 131-145.
-
Corradini SG, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, Cantafora A, Capocaccia L, Ziparo V, Stipa V, Chirletti P, Caronna R, Lomanto D, Attili AF 2000 Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile.
Gastroenterology 118: 912-920.
*
-
Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW 2007 A pravastatin dose-escalation study in systemic lupus erythematosus.
Rheumatol. Int. 27: 1071-1077.
*
-
Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M 2006 Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c.
J. Biol. Chem. 281: 6211-6218.
*
-
Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, Tall AR 2003 Retinoic acid receptor-mediated induction of ABCA1 in macrophages.
Mol. Cell. Biol. 23: 7756-7766.
*
-
Costet P, Luo Y, Wang N, Tall AR 2000 Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor.
J. Biol. Chem. 275: 28240-28245.
*
-
Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, Bissada N, Staels B, Fruchart JC, Fievet C, Joseph-George AM, Wasserman WW, Hayden MR 2005 Complete functional rescue of the ABCA1-/-mouse by human BAC transgenesis.
J. Lipid Res. 46: 1113-1123.
*
-
Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A 2008 Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
Pharmacogenomics 9: 1217-1227.
-
Crabb DW, Liangpunsakul S 2006 Alcohol and lipid metabolism.
J. Gastroenterol. Hepatol. 21 Suppl. 3: S56-S60.
*
-
Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM 1997 Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy.
J. Clin. Invest. 100: 2562-2567.
*
-
Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR 2007 Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
Mech. Ageing Dev. 128: 558-565.
-
Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G 2004 LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport.
Biochem. Soc. Trans. 32: 92-96.
*
-
Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY 1998 Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors.
J. Lipid Res. 39: 2192-2200.
*
-
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER 1992 Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?
Hepatology 15: 858-862.
-
Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M 1996 Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.
Dig. Dis. Sci. 41: 809-815.
-
Crosignani A, Del Puppo M, Longo M, De Fabiani E, Caruso D, Zuin M, Podda M, Javitt NB, Kienle MG 2007 Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease.
Clin. Chim. Acta 382: 82-88.
*
-
Cui J, Heard TS, Yu J, Lo JL, Huang L, Li Y, Schaeffer JM, Wright SD 2002 The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate.
J. Biol. Chem. 277: 25963-25969.
*
-
Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD 2003 Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump.
J. Biol. Chem. 278: 10214-10220.
*
-
Cui J, Lew J-L, Zhao A, Huang L, Wright SD 2004 The farnesoid X receptor controls gene expression in a ligand and promoter-selective fashion.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 32. June 18-19. *
-
Cui NQ, Zhang SK, Cui YF, Li DH, Chen C, Wu XZ 2005 Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones.
Hepatobiliary Pancreat Dis. Int. 4: 117-120.
*
-
Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM, Caira F, Veyssiere G, Mangelsdorf DJ, Lobaccaro JM 2006 Liver X receptors regulate adrenal cholesterol balance.
J. Clin. Invest. 116: 1902-1912.
*
-
Cundiff DK, Lanou AJ, Nigg CR 2007 Relation of omega-3 fatty acid intake to other dietary factors known to reduce coronary heart disease risk.
Am. J. Cardiol. 99: 1230-1233.
*
-
Cunnane SC, Manku MS, Horrobin DF 1979 The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes.
Med. Hypotheses 5: 403-414.
-
Cuomo R, Rodino S, Rizzoli R, Simoni P, Roda E, Cantoni L, Rizzardini M, De Rosa G, Le Grazie C, Di Padova C, et al 1991 Bile and biliary lipid secretion in rats with hexachlorobenzene-induced porphyria. Effect of S-adenosyl-L-methionine administration.
J. Hepatol. 12: 87-93.
-
Czaja AJ 1999 Variant forms of autoimmune hepatitis.
Curr. Gastroenterol. Rep. 1: 63-70.
-
Czech C, Burns MP, Vardanian L, Augustin A, Jacobsen H, Baumann K, Rebeck GW 2007 Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase.
J. Neurochem. 101: 929-936.
-
Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX, Tang CK 2008 The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in ApoE-/- mice.
J. Cardiovasc. Pharmacol. 51: 467-475.
-
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG 2005 Clinical analysis of primary biliary cirrhosis: a report of 42 cases.
Beijing Da Xue Xue Bao 37: 410-414.
-
Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT 2008 Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women.
Eur. J. Clin. Nutr. 62: 386-394.
*
-
Damiano F, Gnoni GV, Siculella L 2008 Functional analysis of rat liver citrate carrier promoter: differential responsiveness to polyunsaturated fatty acids.
Biochem. J. Sep 16 [Epub ahead of print].
*
-
Damsgaard CT, Frokiaer H, Andersen AD, Lauritzen L 2008 Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men.
J. Nutr. 138: 1061-1066.
*
-
Damsgaard CT, Schack-Nielsen L, Michaelsen KF, Fruekilde MB, Hels O, Lauritzen L 2006 Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants.
J. Nutr. 136: 94-99.
*
-
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
N. Engl. J. Med. 350: 1387-1397.
*
-
Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM 2006 Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy.
Obstet. Gynecol. 107: 106-114.
-
Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K 2006 Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes.
Biochimie 88: 309-318.
-
Das A, Fernandez-Zapico ME, Cao S, Yao J, Fiorucci S, Hebbel RP, Urrutia R, Shah VH 2006 Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration.
J. Biol. Chem. 281: 39105-39113.
*
-
Das SK, Chakrabarti R 2006 Role of PPAR in cardiovascular diseases.
Recent Patents Cardiovasc. Drug Discov. 1: 193-209.
-
Das UN 2007 A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis.
Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268.
*
-
Das UN 2008 Do polyunsaturated fatty acids behave like an endogenous "polypill"?
Med. Hypotheses 70: 430-434.
-
Dastani Z, Engert JC, Genest J, Marcil M 2006 Genetics of high-density lipoproteins.
Curr. Opin. Cardiol. 21: 329-335.
-
Davi G, Falco A 2005 Oxidant stress, inflammation and atherogenesis.
Lupus 14: 760-764.
-
David A, Fridlich R, Aviram I 2005 The presence of membrane proteinase 3 in neutrophil lipid rafts and its colocalization with FcgammaRIIIb and cytochrome b558.
Exp. Cell Res. 308: 156-165.
*
-
Davidson MH 2006 Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Expert Opin. Drug Saf. 5: 145-156.
-
Davidson MH, Armani A, McKenney JM, Jacobson TA 2007 Safety considerations with fibrate therapy.
Am. J. Cardiol. 99: S3-S18.
*
-
Davies R, Schuurman A, Barker CR, Clothier B, Chernova T, Higginson FM, Judah DJ, Dinsdale D, Edwards RE, Greaves P, Gant TW, Smith AG 2005 Hepatic gene expression in protoporphyic fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool.
Am. J. Pathol. 166: 1041-1053.
*
-
Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW 2008 Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 like 1 (NPC1L1).
Atheroscler. Suppl. Jun 26 [Epub ahead of print].
-
Davis KG, Wertin TM, Schriver JP 2003 The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model.
Obes. Surg. 13: 865-868.
-
Davis RA, Attie AD 2008 Deletion of the ileal basolateral bile acid transporter identifies the cellular sentinels that regulate the bile acid pool.
Proc. Natl. Acad. Sci. U.S.A. 105: 4965-4966.
*
-
Davis RA, Miyake JH, Hui TY, Spann NJ 2002 Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP.
J. Lipid Res. 43: 533-543.
*
-
Davis W Jr, Boyd JT, Ile KE, Tew KD 2004 Human ATP-binding cassette transporter-2 (ABCA2) positively regulates low-density lipoprotein receptor expression and negatively regulates cholesterol esterification in Chinese hamster ovary cells.
Biochim. Biophys. Acta 1683: 89-100.
*
-
Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS 2003 Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice.
J. Biol. Chem. 278: 33920-33927.
*
-
de Campo A, Toplak H, Wascher TC, Schallmoser K, Friehs A, Schmidt H, Kostner GM 1999 Evaluation of a newly discovered LDL receptor mutation (exon 10, GAC>AAC, D271N, "FH Graz-1") in familial hypercholesterolemia - a family study.
Acta Med. Austriaca 26: 20-25.
-
De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M 2001 The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis…
J. Biol. Chem. 276: 30708-30716.
*
-
De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M 2003 Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle.
J. Biol. Chem. 278: 39124-39132.
*
-
De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M 2004 Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways.
Biochimie 86: 771-778.
-
De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A 2007 Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes.
Lab. Invest. 87: 792-806.
*
-
De Luis D, Aller R, Zarzuelo S 2006 Dietary salt in the era of anthypertensive drugs.
Med. Clin. (Barc.) 127: 673-675.
-
| |
